Exosome Diagnostics, Inc., a subsidiary of mdxhealth, is commercializing minimally invasive molecular diagnostics in blood and urine to enable doctors to select optimal therapies for cancer and other diseases. Exosomes are lipid bilayer covered microvesicles shed by solid tumors into body fluids, such as blood and urine. Exosomes contain nucleic acid profiles of cancers and other diseases. In published studies, Exosome Diagnostics has demonstrated the ability to extract exosomes from the blood and urine of patients, and to detect with high sensitivity and specificity key genes and gene mutations associated with a variety of cancers.
Looking for a particular Exosome Diagnostics employee's phone or email?
The Exosome Diagnostics annual revenue was $26.2 million in 2026.
Nikki Malie is the Director, Market Access of Exosome Diagnostics.
84 people are employed at Exosome Diagnostics.
Exosome Diagnostics is based in Waltham, Massachusetts.
The NAICS codes for Exosome Diagnostics are [6215, 62, 62151, 621].
The SIC codes for Exosome Diagnostics are [807, 80].